

COVID-19 Vaccine Information Brief

December 8, 2021

Changes to the document from the previous version are highlighted in yellow.

IMPORTANT/NEW COVID-19 Vaccine Information - COMIRNATY

- **PFIZER TRANSITION TO COMIRNATY**
- **Comirnaty Ordering Availability**
- COVID-19 Vaccine Redistribution

Pfizer Transition to Comirnaty COVID-19 Vaccine

A new formulation of Pfizer vaccine for adults/adolescents, known as Comirnaty, will be available to Iowa healthcare providers. Comirnaty is the first COVID-19 vaccine to receive [full FDA approval](#). The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals. The Comirnaty formulation will have a distinctive **GRAY** cap and:

- Will be available in smaller 300-dose configurations
- **Does not** require diluent
- May be stored at 2-8°C (36-46°F) for up to 10 weeks
- Can be used on individuals 12 years of age and older

Iowa will not be able to order Comirnaty until the current Pfizer inventory in the state is utilized. THE VACCINE ALLOCATION SURVEY ON DECEMBER 13, 2021, WILL NOT INCLUDE PFIZER ADOLESCENT/ADULT VACCINE IN ORDER TO UTILIZE EXISTING INVENTORY IN THE STATE. Redistribution of Pfizer vaccine may be necessary for providers who need Pfizer vaccine.

Healthcare providers should utilize existing Pfizer formulations (1170 and 450 dose packs) to the greatest extent possible. **CDC recommends provider sites should ideally carry only one Pfizer adult formulation at a time.** In order to avoid mistakes during this **period of transition** when both products may be in circulation, these products should not be offered/administered at the same time. Shipping containers CANNOT be used to store Comirnaty vaccines.

Comirnaty Ordering Availability

- CDC will review Iowa's progress and use of current Pfizer in-field inventory on a weekly basis to assess the need and ability to order Comirnaty.
- CDC will notify Iowa when Comirnaty vaccine will be available to order for providers based on inventory levels of existing Pfizer 1170 and 450 dose packs.

- Iowa will not be able to order Comirnaty until the current Pfizer inventory in the state is significantly reduced/utilized
 - CDC will retire the current Pfizer 1170 packs ordering and transition to the Pfizer Comirnaty formulation
 - Minimum Order Quantity of Comirnaty will be 300 doses
 - Health care providers should utilize existing Pfizer formulations (1170 and 450 dose packs) to the greatest extent possible.
 - LPHAs and healthcare providers should collaborate to redistribute Pfizer COVID-19 vaccine inventory to reduce statewide vaccine inventory.
 - CDC's intent is health care providers will only have two formulations of Pfizer COVID-19 vaccine in inventory
 - Comirnaty Vaccine - 12 ≤ years (Gray Cap)
 - Pediatric Vaccine - 5-11 years (Orange Cap)
-

COVID-19 Vaccine Redistribution

The [Vaccine Redistribution Policy and Process](#) and [Vaccine Redistribution Form](#) is required for each redistribution. Instructions for LPHAs to view provider IRIS inventory, along with COVID-19 Vaccine inventory maps, are posted to the HAN *3 COVID-19 Vaccine folder under the *1 Vaccine Inventory Maps. Questions regarding COVID-19 vaccine redistribution and the transfer of COVID-19 vaccine can be directed to 1-800-831-6293 ext. 1 or COVID19Vaccine@idph.iowa.gov.



The redistribution of COVID-19 vaccines and the physical transfer of vaccine between COVID-19 vaccination providers **MUST ONLY** occur after IDPH approval and IRIS transfer is complete. Inventory adjustments or redistribution of COVID-19 vaccine without IDPH approval may result in the loss of COVID-19 vaccine provider status and removal of COVID-19 vaccines.

The following are requirements for the redistribution of COVID-19 vaccine:

- Redistribution will ONLY be allowed between IDPH approved COVID-19 vaccine providers
- **Redistribution MUST be completed prior to physically transferring COVID-19 vaccine**
- Redistribution must be completed before administration of COVID-19 vaccine
- Redistribution will require completion of the COVID-19 Vaccine Redistribution Form and prior approval by IDPH; IDPH will approve all requests within 24 hours
- Immunization Program staff will initiate the transfer of doses in the initiating organization's IRIS account, and will accept the transfer of doses in the receiving organization's IRIS account
- Transferring provider is responsible for the physical transfer of vaccine and ancillary supplies
Receiving organization is required to document COVID-19 vaccine doses administered in IRIS

Questions regarding COVID-19 vaccine can be directed to 1-800-831-6293 ext. 1 or COVID19Vaccine@idph.iowa.gov.

Pfizer Product Overview

Description	Formulations		
	<i>Dilute Prior to Use</i>	<i>Do Not Dilute</i>	<i>Dilute Prior to Use</i>
Age Group	12 years and older	12 years and older	5 to <12 years*
Vial Cap Color	PURPLE  	GRAY (Coming soon)  	ORANGE  
Dose	30 mcg	30 mcg	10 mcg
Injection Volume	0.3 mL	0.3 mL	0.2 mL
Fill Volume (before dilution)	0.45 mL	2.25 mL	1.3 mL
Amount of Diluent* Needed per Vial	1.8 mL	NO DILUTION	1.3 mL
Doses per Vial	6 doses per vial (after dilution)	6 doses per vial	10 doses per vial (after dilution)
Storage Conditions			
ULT Freezer (-90°C to -60°C)	9 months	6 months	6 months
Freezer (-25°C to -15°C)	2 weeks	N/A	N/A
Refrigerator (2°C to 8°C)	1 month	10 weeks	10 weeks

*Diluent: 0.9% sterile Sodium Chloride Injection, USP (non-bacteriostatic; DO NOT USE OTHER DILUENTS)

Manufacturer	NDC Number	Product Name	Name	Configuration	Notes
Pfizer	59267-1000-02	Pfizer Covid Vaccine 195 vial tray	PBS 1170 (Purple Cap)	6 dose vial, diluent required	Retiring in December
Pfizer	59267-1025-04	Pfizer Covid Vaccine 10ct Adult	Adult Tris Comirnaty (Gray Cap)	6 dose vial, no diluent	Available to order when state supply of Pfizer in the field has been utilized
Pfizer	59267-1055-04	Pfizer Covid Vaccine 10ct Pediatric 10 mcg	Pediatric (Orange Cap)	10 dose vial, diluent required	Continuing for age 5-11 year olds